228 related articles for article (PubMed ID: 15804266)
1. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.
Lamberti P; Zoccolella S; Armenise E; Lamberti SV; Fraddosio A; de Mari M; Iliceto G; Livrea P
Eur J Neurol; 2005 May; 12(5):365-8. PubMed ID: 15804266
[TBL] [Abstract][Full Text] [Related]
2. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
[TBL] [Abstract][Full Text] [Related]
3. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
[TBL] [Abstract][Full Text] [Related]
4. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
Anamnart C; Kitjarak R
J Clin Neurosci; 2021 Jun; 88():226-231. PubMed ID: 33992189
[TBL] [Abstract][Full Text] [Related]
5. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
[TBL] [Abstract][Full Text] [Related]
6. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease.
Rogers JD; Sanchez-Saffon A; Frol AB; Diaz-Arrastia R
Arch Neurol; 2003 Jan; 60(1):59-64. PubMed ID: 12533089
[TBL] [Abstract][Full Text] [Related]
7. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Miller JW; Selhub J; Nadeau MR; Thomas CA; Feldman RG; Wolf PA
Neurology; 2003 Apr; 60(7):1125-9. PubMed ID: 12682318
[TBL] [Abstract][Full Text] [Related]
8. Serum homocysteine and physical exercise in patients with Parkinson's disease.
Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
[TBL] [Abstract][Full Text] [Related]
9. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
[TBL] [Abstract][Full Text] [Related]
10. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
Camicioli RM; Bouchard TP; Somerville MJ
Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
[TBL] [Abstract][Full Text] [Related]
11. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations.
Ozer F; Meral H; Hanoglu L; Aydemir T; Yilsen M; Cetin S; Ozturk O; Seval H; Koldas M
Neurol Res; 2006 Dec; 28(8):853-8. PubMed ID: 17288745
[TBL] [Abstract][Full Text] [Related]
12. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.
Zoccolella S; Lamberti P; Iliceto G; Diroma C; Armenise E; Defazio G; Lamberti SV; Fraddosio A; de Mari M; Livrea P
Clin Chem Lab Med; 2005; 43(10):1107-10. PubMed ID: 16197306
[TBL] [Abstract][Full Text] [Related]
13. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
[TBL] [Abstract][Full Text] [Related]
14. Homocysteine in restless legs syndrome.
Bachmann CG; Guth N; Helmschmied K; Armstrong VW; Paulus W; Happe S
Sleep Med; 2008 May; 9(4):388-92. PubMed ID: 17900981
[TBL] [Abstract][Full Text] [Related]
15. Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.
dos Santos EF; Busanello EN; Miglioranza A; Zanatta A; Barchak AG; Vargas CR; Saute J; Rosa C; Carrion MJ; Camargo D; Dalbem A; da Costa JC; de Sousa Miguel SR; de Mello Rieder CR; Wajner M
Metab Brain Dis; 2009 Jun; 24(2):257-69. PubMed ID: 19294496
[TBL] [Abstract][Full Text] [Related]
16. Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa.
Siniscalchi A; Gallelli L; Mercuri NB; Ibbadu GF; De Sarro G
Nutr Neurosci; 2006; 9(1-2):11-6. PubMed ID: 16910165
[TBL] [Abstract][Full Text] [Related]
17. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Postuma RB; Espay AJ; Zadikoff C; Suchowersky O; Martin WR; Lafontaine AL; Ranawaya R; Camicioli R; Lang AE
Neurology; 2006 Jun; 66(12):1941-3. PubMed ID: 16801668
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of total plasma homocysteine in subjects with hyperhomocysteinemia due to folate or cobalamin deficiency.
Guttormsen AB; Schneede J; Ueland PM; Refsum H
Am J Clin Nutr; 1996 Feb; 63(2):194-202. PubMed ID: 8561060
[TBL] [Abstract][Full Text] [Related]
19. Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients.
Belcastro V; Pierguidi L; Castrioto A; Menichetti C; Gorgone G; Ientile R; Pisani F; Rossi A; Calabresi P; Tambasco N
Eur J Neurol; 2010 May; 17(5):661-5. PubMed ID: 20050890
[TBL] [Abstract][Full Text] [Related]
20. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]